Ex vivo thrombin generation in patients with venous thromboembolic disease or atrial fibrillation on long-term oral anticoagulation

Clinical and Applied Thrombosis/Hemostasis

Volumn 16, Issue 6, 2010, Pages 614-621

  Musiał, Jacek ^a   Brzezinska Kolarz B ^a   Zolcinski M ^a   Lelakowski, J ^a   Szczeklik, A ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

atrial fibrillation; factor VIII; oral anticoagulation; thrombin generation; venous thromboembolism

Indexed keywords

ACENOCOUMAROL; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; PROTEIN C; THROMBIN ANTITHROMBIN COMPLEX; VITAMIN K GROUP;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SKIN INCISION; VENOUS BLOOD; VENOUS THROMBOEMBOLISM;

ACENOCOUMAROL; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; CASE-CONTROL STUDIES; FACTOR VIII; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LONG-TERM CARE; MALE; MIDDLE AGED; PROTHROMBIN; THROMBIN; VENOUS THROMBOEMBOLISM;

EID: 78650316039     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029610363128     Document Type: Article

References (30)

1. Kirkwood TBL. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost. 1983 ; 49 (3). 238-244.
2. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., Hylek E. The pharmacology and management of the vitamin K antagonists. The Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest. 2004 ;126(3 suppl): 204S-233S.
3. Brummel KE, Paradis SG, Branda RF, Mann KG Oral anticoagulant thresholds. Circulation. 2001 ; 104 (19). 2311-2317.
4. O'Donnell J., Mumford AD, Manning RA, Laffan MA Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. Br J Haematol. 2001 ; 115 (3). 687-691.
5. Bank I., van de Poel MH, Coppens M., et al. Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c. A prospective family cohort study. Thromb Haemost. 2007 ; 98 (5). 1040-1044.
6. Tirado I., Mateo J., Soria JM, et al. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost. 2005 ; 93 (3). 468-474.
7. Dielis AW, Castoldi E., Spronk HM, et al. Cogulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost. 2008 ; 6 (1). 125-131.
8. Amiral J., Grosley B., Boyer-Neumann C., et al. New direct assay of free protein S antigen using two distinct monoclonal antibodies specific for free form. Blood Coagul Fibrinolysis. 1994 ; 5 (2). 179-186. (Pubitemid 24138050)
9. Brandt JT, Triplett DA, Alving B., Scharrer I. Criteria for the diagnosis of lupus anticoagulans: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995 ; 74 (4). 1185-1190.
10. Loizou S., McCrea JD, Rudge AC, Reynolds R., Boyle CL, Harris EN Measurement of anticardiolipin antibodies by an enzyme linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol. 1985 ; 62 (3). 738-745.
11. Arvieux J., Roussel B., Jacob MC, Colomb Mg. Hyperlink "http://www.ncbi.nlm.nih.gov/pubmed/1940391?itool=EntrezSystem 2.PEntrez.Pubmed.Pubmed-ResultsPanel Pubmed-RVDocSum&or dinalpos=4" Measurement of anti-phospholipid antibodies by ELISA using beta 2-glycoprotein I as an antigen. J Immunol Methods. 1991 ; 143 (2). 223-229.
12. Kyrle PA, Westwick J., Scully MF, Kakkar VV, Lewis GP Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation ex vivo in man. Effect of low-dose aspirin. Thromb Haemost. 1987 ; 57 (1). 62-69.
13. Undas A., Undas R., Musia J., Szczeklik A. A low dose of aspirin (75 mg/day) lowers thrombin generation to a similar extent as a high dose of aspirin (300 mg/day). Blood Coagul Fibrinolysis. 2000 ; 11 (3). 231-234.
14. Kyrle PA, Brockmeier J., Weltermann A., et al. Inhibition rather than enhancement of hemostatic system activation during initiation of oral anticoagulant treatment. Thromb Haemost. 1997 ; 77 (4). 685-689.
15. Butenas S., van't Veer C., Mann KG HYPERLINK "http:// www.ncbi.nlm.nih.gov/pubmed/9261172?itool=EntrezSystem2. PEntrez.Pubmed.Pubmed- ResultsPanel.Pubmed-RVDocSum& ordinalpos=48" Evaluation of the initiation phase of blood coagu lation using ultrasensitive assays for serine proteases. J Biol Chem. 1997 ; 272 (34). 21527-21533.
16. Hemker HC, Wielders S., Kessels H., Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost. 1993 ; 70 (4). 617-624.
17. Szczeklik A., Krzanowski M., Góra P., Radwan J. Antiplatelet drugs and generation of thrombin in clotting blood. Blood. 1992 ; 80 (8). 2006-2011.
18. Undas A., Brummel K., Musial J., Mann KG, Szczeklik A. Blood coagulation at the site of microvascular injury: effects of low-dose aspirin. Blood. 2001 ; 98 (8). 2423-2431.
19. Altman R., Scazziota A., Herrera L., Gonzales C. Relationship between thrombin generation and international normalized ratio in patients receiving oral vitamin K antagonist therapy. J Thromb Haemost. 2007 ; 5 (7). 1552-1554.
20. Undas A., Brzezinska-Kolarz B., Orfeo T., et al. Blood coagulation at the site of microvacular injuy in healthy and coumadin-treated subjects heterogenous for factor V Leiden mutation. Thromb Haemost. 2007 ; 98 (5). 1024-1030.
21. Kamphuisen PW, Eikenboom JCJ, Bertina RM Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol. 2001 ; 21 (5). 731-738.
22. Gustafsson C., Blombäck M., Britton M., Hamsten A., Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke. 1990 ; 21 (1). 47-51.
23. Ederhy S., Di Angelantonio E., Mallat Z., et al. Levels of circulating procoagulant particles in nonvalvular atrial fibrillation. Am J Cardiol. 2007 ; 100 (6). 989-994.
24. Heeringa J., Conway DS, van der Kuip DA, et al. A longitudinal population-based study of prothombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990-1999. J Thromb Haemost. 2006 ; 4 (9). 1944-1949.
25. O'Donnell J., Mumford AD, Manning RA, Laffan MA Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. Br J Haematol. 2001 ; 115 (3). 687-691.
26. Lind SE, Callas PW, Golden EA, Joyner KA Jr, Ortel TL. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinolysis. 1997 ; 8 (1). 48-53.
27. van Geest-Daalderop JH, Hutten BA, Péquériaux NC, Haas FJ, Levi M., Sturk A. The influence on INRs and coagulation factors of the time span between blood sample collection and intake of phenprocoumon or acenocoumarol: consequences for assessment of the dose. Thromb Haemost. 2007 ; 98 (4). 738-746.
28. van't Veer C., Golden NJ, Kalafatis M., Mann KG Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. J Biol Chem. 1997 ; 272 (12). 7983-7994.
29. van't Veer C., Mann KG Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem. 1997 ; 272 (7). 4367-4377.
30. Mitusch R., Siemens HJ, Garbe M., Wagner T., Sheikhzadeh A., Diederich KW Detection of hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost. 1996 ; 75 (2). 219-223.